




FIG. 1A




FIG. 1B

2 / 21





FIG. 2

3 / 21




FIG. 3




FIG. 4A




FIG. 4B




FIG. 5

6 / 21




FIG. 6




FIG. 7





FIG. 8






FIG. 10A

FIG. 10B




FIG. 10C

FIG. 10D

FIG. 10E




FIG. 10F

FIG. 10G




FIG. 11




FIG. 12A




FIG. 12B




FIG. 13A




FIG. 13B




FIG. 14A




FIG. 14B




FIG. 14C

Trastuzumab HC-S298G, T299A-ESSY, LC-SSEY control



FIG. 15A

Sample after rxn 1: 4C for 45min




FIG. 15B

Sample after rxn 2: 30C for 120min




FIG. 15C

MPC 4+2: Sample after purification




FIG. 15D




FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D

Conjugation of Cytotoxic Payloads to Dual Tagged Trastuzumab:
Conjugation and Material Validation




FIG. 17




FIG. 18

Conjugation of Cytotoxic Payloads to Dual Tagged Trastuzumab




FIG. 19

21 / 21





FIG. 20






FIG. 22